270 related articles for article (PubMed ID: 37427356)
1. Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation.
Gjermeni D; Saglam NP; Olivier CB; Kühlkamp V
Eur Heart J Open; 2023 Jul; 3(4):oead065. PubMed ID: 37427356
[TBL] [Abstract][Full Text] [Related]
2. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
Europace; 2014 Oct; 16(10):1443-9. PubMed ID: 25115168
[TBL] [Abstract][Full Text] [Related]
3. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
[TBL] [Abstract][Full Text] [Related]
4. Renal function and periprocedural complications in patients undergoing left atrial catheter ablation: A comparison between uninterrupted direct oral anticoagulants and phenprocoumon administration.
Erhard N; Bahlke F; Spitzauer L; Englert F; Popa M; Bourier F; Reents T; Lennerz C; Kraft H; Maurer S; Tunsch-Martinez A; Syväri J; Tydecks M; Telishevska M; Lengauer S; Hessling G; Deisenhofer I; Kottmaier M
Clin Res Cardiol; 2024 Jan; ():. PubMed ID: 38261026
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
6. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
8. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
10. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
[TBL] [Abstract][Full Text] [Related]
11. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events.
Nakamura K; Naito S; Sasaki T; Take Y; Minami K; Kitagawa Y; Motoda H; Inoue M; Otsuka Y; Niijima K; Yamashita E; Sugai Y; Kumagai K; Koyama K; Funabashi N; Oshima S
Europace; 2019 Feb; 21(2):259-267. PubMed ID: 29982562
[TBL] [Abstract][Full Text] [Related]
12. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
Hohnloser SH; Basic E; Nabauer M
Clin Res Cardiol; 2017 Aug; 106(8):618-628. PubMed ID: 28293797
[TBL] [Abstract][Full Text] [Related]
14. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Zylla MM; Pohlmeier M; Hess A; Mereles D; Kieser M; Bruckner T; Scholz E; Zitron E; Schweizer PA; Katus HA; Thomas D
Am J Cardiol; 2015 Mar; 115(5):635-40. PubMed ID: 25591898
[TBL] [Abstract][Full Text] [Related]
17. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
[TBL] [Abstract][Full Text] [Related]
19. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
20. Catheter ablation in adult congenital heart disease on uninterrupted oral anticoagulation: Is it safe? Data from a large single-center study.
Foerschner L; Kriesmair J; Telishevska M; Kottmaier M; Bourier F; Reents T; Lengauer S; Lennerz C; Krafft H; Maurer S; Popa M; Kolb C; Deisenhofer I; Hessling G
Heart Rhythm; 2022 Apr; 19(4):648-655. PubMed ID: 34958942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
